NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

McCrory DC, Williams JW, Dolor RJ, et al. Management of Allergic Rhinitis in the Working-Age Population. Rockville (MD): Agency for Healthcare Research and Quality (US); 2003 Mar. (Evidence Reports/Technology Assessments, No. 67.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Management of Allergic Rhinitis in the Working-Age Population

Management of Allergic Rhinitis in the Working-Age Population.

Show details

References

  1. Adelsberg B R. Sedation and performance issues in the treatment of allergic conditions. [Review] Arch Intern Med. 1997;157(5):494–500. [PubMed: 9066452]
  2. Alves B, Sheikh A, Hurwitz B, et al. Allergen injection immunotherapy for seasonal allergic rhinitis (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software.
  3. American Academy of Allergy, Asthma & Immunology. The allergy report. Milwaukee, WI: American Academy of Allergy, Asthma & Immunology, Inc.; 2000.
  4. Anderson H R, Pottier A C, Strachan D P. Asthma from birth to age 23: incidence and relation to prior and concurrent atopic disease. Thorax. 1992;47(7):537–42. [PMC free article: PMC463865] [PubMed: 1412098]
  5. Andri L, Senna GE, Betteli C, et al. Combined treatment of allergic rhinitis with terfenadine and nimesulide, a non-steroidal antiinflammatory drug. Allerg Immunol (Paris) 1992;24(8):313–4, 317–9. [PubMed: 1418392]
  6. Antonicelli L, Bilò M B, Pucci S. et al. Efficacy of an air-cleaning device equipped with a high efficiency particulate air filter in house dust mite respiratory allergy. Allergy. 1991;46(8):594–600. [PubMed: 1789401]
  7. Ariano R, Kroon A M, Augeri G. et al. Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial. Allergy. 1999;54(4):313–9. [PubMed: 10371089]
  8. Arvidsson M B, Löwhagen O, Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol. 2002;109(5):777–83. [PubMed: 11994699]
  9. Backhouse C I, Finnamore V P, Gosden C W. Treatment of seasonal allergic rhinitis with flunisolide and terfenadine. J Int Med Res. 1986;14(1):35–41. [PubMed: 3082694]
  10. Bellanti J A, Wallerstedt D B. Allergic rhinitis update: epidemiology and natural history. [Review] Allergy Asthma Proc. 2000;21(6):367–70. [PubMed: 11191103]
  11. Benincasa C, Lloyd R S. Evaluation of fluticasone propionate aqueous nasal spray taken alone and in combination with cetirizine in the prophylactic treatment of seasonal allergic rhinitis. Drug Invest. 1994;8(4):225–33.
  12. Berger W E, Fineman S M, Lieberman P. et al. Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Rhinitis Study Groups. Ann Allergy Asthma Immunol. 1999;82(6):535–41. [PubMed: 10400480]
  13. Bernstein I L, Tennenbaum J, Georgakis N. et al. Fraction A: a new immunotherapeutic approach for ragweed pollinosis. Int Arch Allergy Appl Immunol. 1976;50(2):181–91. [PubMed: 1107233]
  14. Bertrand B, Jamart J, Marchal J L. et al. Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: a double-blind multicentre study. Rhinology. 1996;34(2):91–6. [PubMed: 8876070]
  15. Biostat. Comprehensive Meta-analysis [computer program]. Version 1.25. Englewood, NJ: Biostat; 1999.
  16. Blainey A D, Phillips M J, Ollier S. et al. Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial rhinitis. A controlled clinical trial. Allergy. 1984;39(7):521–8. [PubMed: 6388401]
  17. Blair H. Natural history of childhood asthma. 20-year follow-up. Arch Dis Child. 1977;52(8):613–9. [PMC free article: PMC1544640] [PubMed: 921306]
  18. Blaiss M S. Quality of life in allergic rhinitis. [Review] Ann Allergy Asthma Immunol. 1999;83(5):449–54. [PubMed: 10582730]
  19. Blanc P D, Trupin L, Eisner M. et al. The work impact of asthma and rhinitis: findings from a population-based survey. J Clin Epidemiol. 2001;54(6):610–8. [PubMed: 11377122]
  20. Bødtger U, Poulsen L K, Jacobi H H. et al. The safety and efficacy of subcutaneous birch pollen immunotherapy -- a one-year, randomised, double-blind, placebo-controlled study. Allergy. 2002;57:297–305. [PubMed: 11906359]
  21. Bousquet J, Bullinger M, Fayol C. et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol. 1994;94(2 Pt 1):182–8. [PubMed: 8064070]
  22. Bousquet J, Frank E, Soussana M. et al. Double-blind, placebo-controlled immunotherapy with a high-molecular-weight, formalinized allergoid in grass pollen allergy. Int Arch Allergy Appl Immunol. 1987;82(34):550–2. [PubMed: 3553031]
  23. Bousquet J, Hejjaoui A, Skassa-Brociek W. et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol. 1987;80(4):591–8. [PubMed: 3668124]
  24. Bousquet J, Hejjaoui A, Soussana M. et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J Allergy Clin Immunol. 1990;85(2):490–7. [PubMed: 2406327]
  25. Bousquet J, Lockey R, Malling H J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. [Review] J Allergy Clin Immunol. 1998;102(4 Pt 1):558–62. [PubMed: 9802362]
  26. Bousquet J, Maasch H J, Hejjaoui A. et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol. 1989;84(4 Pt 1):546–56. [PubMed: 2677092]
  27. Bousquet J, van Cauwenberge P, Khaltaev N. et al. Allergic rhinitis and its impact on asthma (ARIA) J Allergy Clin Immunol. 2001;108:S147–336. [PubMed: 11707753]
  28. Briggs A H, O'Brien B J. The death of cost-minimization analysis? [Review] Health Econ. 2001;10(2):179–84. [PubMed: 11252048]
  29. Bronsky E, Boggs P, Findlay S. et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol. 1995;96(2):139–47. [PubMed: 7636050]
  30. Brooks C D, Francom S F, Peel B G. et al. Spectrum of seasonal allergic rhinitis symptom relief with topical corticoid and oral antihistamine given singly or in combination. Am J Rhinol. 1996;10(3):193–9.
  31. Brooks C D, Karl K J. Hay fever treatment with combined antihistamine and cyclooxygenase-inhibiting drugs. J Allergy Clin Immunol. 1988;81(6):1110–7. [PubMed: 2897986]
  32. Brunet C, Bedard P M, Lavoie A. et al. Allergic rhinitis to ragweed pollen. I. Reassessment of the effects of immunotherapy on cellular and humoral responses. J Allergy Clin Immunol. 1992;89(1 Pt 1):76–86. [PubMed: 1370510]
  33. Brydon M. The effectiveness of a peripatetic allergy nurse practitioner service in managing atopic allergy in general practice--a pilot study. Clin Exp Allergy. 1993;23(12):1037–44. [PubMed: 10779298]
  34. Bukstein D A, Biondi R M, Blumenthal M M. et al. Tilarin in combination with astemizole. Allergy. 1996;51(28 Suppl):20–7. [PubMed: 8651473]
  35. Burton W N, Conti D J, Chen C Y. et al. The impact of allergies and allergy treatment on worker productivity. J Occup Environ Med. 2001;43(1):64–71. [PubMed: 11201771]
  36. Busse W, Janssens M, Eisen G. A multicenter, double-blind, randomized, placebo-controlled trial comparing the efficacy and tolerability of levocabastine-oxymetazoline nasal spray with levocabastine and oxymetazoline alone in the symptomatic treatment of seasonal allergic rhinitis. Am J Rhinol. 1996;10(2):105–11.
  37. Camilleri A E. Information leaflets in the rhinitis clinic? J Laryngol Otol. 1991;105(4):282–4. [PubMed: 2026941]
  38. Centers for Disease Control and Prevention, National Center for Health Statistics. Current estimates from the National Health Interview Survey, 1996. Vital and Health Statistics, Series 10, No. 200. DHHS Publication No. (PHS) 99-1528. Hyattsville, MD: US Department of Health and Human Services. October 1999.
  39. Cloosterman S G, Schermer T R, Bijl-Hofland I D. et al. Effects of house dust mite avoidance measures on Der p 1 concentrations and clinical condition of mild adult house dust mite-allergic asthmatic patients, using no inhaled steroids. Clin Exp Allergy. 1999;29(10):1336–46. [PubMed: 10520054]
  40. Cockburn I M, Bailit H L, Berndt E R. et al. Loss of work productivity due to illness and medical treatment. J Occup Environ Med. 1999a;41(11):948–53. [PubMed: 10570499]
  41. Cockburn I M, Bailit H L, Berndt E R. et al. Costing out care: when antihistamines go to work. Bus Health. 1999b;17(3):49–50. [PubMed: 10387170]
  42. Cockcroft D W, Cuff M T, Tarlo S M. et al. Allergen injection therapy with glutaraldehyde-modified--ragweed pollen-tyrosine adsorbate. A double-blind trial. J Allergy Clin Immunol. 1977;60(1):56–62. [PubMed: 406299]
  43. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: L. Erlbaum Associates; 1988.
  44. Cook PR, Farias C. The safety of allergen immunotherapy: a literature review. [Review]. Ear Nose Throat J 1998;77(5):378–9, 383–8. [PubMed: 9615518]
  45. Corey J P, Kemker B J, Branca J T. et al. Health status in allergic rhinitis. Otolaryngol Head Neck Surg. 2000;122(5):681–5. [PubMed: 10793346]
  46. Creticos P S, Reed C E, Norman P S. et al. Ragweed immunotherapy in adult asthma. N Engl J Med. 1996;334(8):501–6. [PubMed: 8559203]
  47. Crystal-Peters J, Crown W H, Goetzel R Z. et al. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care. 2000;6(3):373–8. [PubMed: 10977437]
  48. Cuffel B, Wamboldt M, Borish L. et al. Economic consequences of comorbid depression, anxiety, and allergic rhinitis. Psychosomatics. 1999;40(6):491–6. [PubMed: 10581977]
  49. D'Souza M F, Pepys J, Wells I D. et al. Hyposensitization with Dermatophagoides pteronyssinus in house dust allergy: a controlled study of clinical and immunological effects. Clin Allergy. 1973;3(2):177–93. [PubMed: 4131252]
  50. de Graaf-in't Veld T, Koenders S, Garrelds I M. et al. The relationships between nasal hyperreactivity, quality of life, and nasal symptoms in patients with perennial allergic rhinitis. J Allergy Clin Immunol. 1996;98(3):508–13. [PubMed: 8828527]
  51. Demoly P, Allaert F - A, Lecasble M. et al. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy. 2002;57:546–54. [PubMed: 12028122]
  52. Diamond L, Gerson K, Cato A. et al. An evaluation of triprolidine and pseudoephedrine in the treatment of allergic rhinitis. Ann Allergy. 1981;47(2):87–91. [PubMed: 7258744]
  53. Dockhorn R, Aaronson D, Bronsky E. et al. Ipratropium bromide nasal spray 0.03% and beclomethasone nasal spray alone and in combination for the treatment of rhinorrhea in perennial rhinitis. Ann Allergy Asthma Immunol. 1999;82(4):349–59. [PubMed: 10227333]
  54. Dockhorn R J, Williams B O, Sanders R L. Efficacy of acrivastine with pseudoephedrine in treatment of allergic rhinitis due to ragweed. Ann Allergy Asthma Immunol. 1996;76(2):204–8. [PubMed: 8595542]
  55. Dolz I, Martinez-Cocera C, Bartolome J M. et al. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy. 1996;51(7):489–500. [PubMed: 8863926]
  56. Donahue J G, Greineder D K, Connor-Lacke L. et al. Utilization and cost of immunotherapy for allergic asthma and rhinitis. Ann Allergy Asthma Immunol. 1999;82(4):339–47. [PubMed: 10227332]
  57. Drouin M A, Yang W H, Horak F. et al. Adding loratadine to topical nasal steroid therapy improves moderately severe seasonal allergic rhinoconjunctivitis. Adv Ther. 1995;12(6):340–9.
  58. Durham S R, Walker S M, Varga E M. et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341(7):468–75. [PubMed: 10441602]
  59. European Agency for Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products European Public Assessment Report (EPAR): Neoclarityn. 2001. Available at: http://www.eudra.org/humandocs/humans/epar/neoclarityn/neoclarityn.htm. Accessed August 31, 2002.
  60. Ewan P W, Alexander M M, Snape C. et al. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy. 1988;18(5):501–8. [PubMed: 3069238]
  61. Fagan J K, Scheff P A, Hryhorczuk D. et al. Prevalence of asthma and other allergic diseases in an adolescent population: association with gender and race. Ann Allergy Asthma Immunol. 2001;86(2):177–84. [PubMed: 11258687]
  62. Falliers C J, Redding M A. Controlled comparison of anew antihistamine-decongestant combination to its individual components. Ann Allergy. 1980;45(2):75–80. [PubMed: 6157338]
  63. Fell WR, Mabry RL, Mabry CS. Quality of life analysis of patients undergoing immunotherapy for allergic rhinitis. Ear Nose Throat J 1997;76(8):528–32, 534–6. [PubMed: 9282460]
  64. Finn A F Jr, Aaronson D, Korenblat P. et al. Ipratropium bromide nasal spray 0.03% provides additional relief from rhinorrhea when combined with terfenadine in perennial rhinitis patients; a randomized, double-blind, active-controlled trial. Am J Rhinol. 1998;12(6):441–9. [PubMed: 9883302]
  65. Fornadley J A, Corey J P, Osguthorpe J D. et al. Allergic rhinitis: clinical practice guideline. Committee on Practice Standards, American Academy of Otolaryngic Allergy. Otolaryngol Head Neck Surg. 1996;115(1):115–22. [PubMed: 8758640]
  66. Francillon C, Burnand B, Frei P. et al. Referral pattern to the allergist for hay fever in a health-care system with open access to specialists. Allergy. 1995;50(12):959–63. [PubMed: 8834824]
  67. Gabriel M, Ng H K, Allan W G. et al. Study of prolonged hyposensitization with D. pteronyssinus extract in allergic rhinitis. Clin Allergy. 1977;7(4):325–39. [PubMed: 589769]
  68. Gani F, Pozzi E, Crivellaro M A. et al. The role of patient training in the management of seasonal rhinitis and asthma: clinical implications. Allergy. 2001;56:65–8. [PubMed: 11167354]
  69. Geller-Bernstein C, Pibourdin J M, Dornelas A. et al. Efficacy of the acaricide: acardust for the prevention of asthma and rhinitis due to dust mite allergy, in children. Allerg Immunol (Paris) 1995;27(5):147–54. [PMC free article: PMC267442] [PubMed: 7662102]
  70. Gilmore T M, Alexander B H, Mueller B A. et al. Occupational injuries and medication use. Am J Industrial Med. 1996;30(2):234–9. [PubMed: 8844055]
  71. Gøtzsche PC, Johansen HK, Hammarquist C, et al. House dust mite control measures for asthma (Cochrane Review). In: The Cochrane Library, Issue 2, 2001. Oxford: Update Software.
  72. Grammer L C, Shaughnessy M A, Bernhard M I. et al. The safety and activity of polymerized ragweed: a double-blind, placebo-controlled trial in 81 patients with ragweed rhinitis. J Allergy Clin Immunol. 1987;80(2):177–83. [PubMed: 3301986]
  73. Grammer L C, Shaughnessy M A, Suszko I M. et al. A double-blind histamine placebo-controlled trial of polymerized whole grass for immunotherapy of grass allergy. J Allergy Clin Immunol. 1983;72(5 Pt 1):448–53. [PubMed: 6355247]
  74. Grammer L C, Zeiss C R, Suszko I M. et al. A double-blind, placebo-controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy. J Allergy Clin Immunol. 1982;69(6):494–9. [PubMed: 7042799]
  75. Grosclaude M, Mees K, Pinelli M E. et al. Cetirizine and pseudoephedrine retard, given alone or in combination, in patients with seasonal allergic rhinitis. Rhinology. 1997;35(2):67–73. [PubMed: 9299654]
  76. Henauer S, Seppey M, Huguenot C. et al. Effects of terfenadine and pseudoephedrine, alone and in combination in a nasal provocation test and in perennial rhinitis. Eur J Clin Pharmacol. 1991;41(4):321–4. [PubMed: 1804647]
  77. Hirsch S R, Kalbfleisch J H, Cohen S H. Comparison of Rinkel injection therapy with standard immunotherapy. J Allergy Clin Immunol. 1982;70(3):183–90. [PubMed: 7108070]
  78. Hirsch S R, Kalbfleisch J H, Golbert T M. et al. Rinkel injection therapy: a multicenter controlled study. J Allergy Clin Immunol. 1981;68(2):133–55. [PubMed: 7019293]
  79. Huss R W, Huss K, Squire E N. et al. Mite allergen control with acaricide fails. J Allergy Clin Immunol. 1994;94(1):27–32. [PubMed: 8027495]
  80. Iliopoulos O, Proud D, Adkinson N F. et al. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. J Allergy Clin Immunol. 1991;87(4):855–66. [PubMed: 2013680]
  81. Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology & N A ;Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology, representing the American Academy of Allergy, Asthma and Immunology; the American College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and ImmunologyAnn Allergy Asthma Immunol 1998 81(5 Pt 2) 478 518. [PubMed: 9860027]
  82. Jüni P, Witschi A, Bloch R. et al. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282(11):1054–60. [PubMed: 10493204]
  83. Juniper E F. Measuring health-related quality of life in rhinitis. [Review] J Allergy Clin Immunol. 1997;99(2):S742–9. [PubMed: 9042066]
  84. Juniper E F, Guyatt G H. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77–83. [PubMed: 2021881]
  85. Juniper E F, Kline P A, Hargreave F E. et al. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 1989;83(3):627–33. [PubMed: 2494249]
  86. Juniper E F, Kline P A, Ramsdale E H. et al. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 1990;85(3):606–11. [PubMed: 2107241]
  87. Keith P K, Haddon J, Birch S. A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis. Rhinocort Study Group. Ann Allergy Asthma Immunol. 2000;84(1):55–62. [PubMed: 10674566]
  88. Kessler R C, Almeida D M, Berglund P. et al. Pollen and mold exposure impairs the work performance of employees with allergic rhinitis. Ann Allergy Asthma Immunol. 2001;87(10):289–95. [PubMed: 11686420]
  89. Kniest F M, Young E, Van Praag M C. et al. Clinical evaluation of a double-blind dust-mite avoidance trial with mite-allergic rhinitic patients. Clin Exp Allergy. 1991;21(1):39–47. [PubMed: 2021877]
  90. Kooistra J B, Pasch R, Reed C E. The effects of air cleaners on hay fever symptoms in air-conditioned homes. J Allergy Clin Immunol. 1978;61(5):315–9. [PubMed: 346629]
  91. Kozma C M, Schulz R M, Sclar D A. et al. A comparison of costs and efficacy of intranasal fluticasone propionate and terfenadine tablets for seasonal allergic rhinitis. Clin Ther. 1996;18(2):334–46. [PubMed: 8733993]
  92. Kroidl R F, Göbel D, Balzer D. et al. Clinical effects of benzyl benzoate in the prevention of house-dust-mite allergy. Results of a prospective, double-blind, multicenter study. Allergy. 1998;53(4):435–40. [PubMed: 9574889]
  93. Krouse J H, Krouse H J. Patient use of traditional and complementary therapies in treating rhinosinusitis before consulting an otolaryngologist. Laryngoscope. 1999;109(8):1223–7. [PubMed: 10443823]
  94. Krouse J H, Krouse H J. Efficacy of immunotherapy based on skin end-point titration. Otolaryngol Head Neck Surg. 2000;123(3):183–7. [PubMed: 10964288]
  95. Lane A P, Pine H S, Pillsbury H C III. Allergy testing and immunotherapy in an academic otolaryngology practice: a 20-year review. Otolaryngol Head Neck Surg. 2001;124(1):9–15. [PubMed: 11228445]
  96. Lanier B Q, Gross R D, Marks B B. et al. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Ann Allergy Asthma Immunol. 2001;86(6):641–8. [PubMed: 11428736]
  97. Lau S K, Wei W I, Van Hasselt C A. et al. A clinical comparison of budesonide nasal aerosol, terfenadine and a combined therapy of budesonide and oxymetazoline in adult patients with perennial rhinitis. Asian Pac J Allergy Immunol. 1990;8(2):109–15. [PubMed: 1709020]
  98. Lebowitz M D, Cassell E J, McCarroll J. Health and the urban environment. XI. The incidence and burden of minor illness in a healthy population: methods, symptoms, and incidence. Am Rev Respir Dis. 1972;106(6):824–34. [PubMed: 4641217]
  99. Lee J, Cummins G, Okamoto L. A descriptive analysis of the use and cost of new-generation antihistamines in the treatment of allergic rhinitis: a retrospective database analysis. Am J Manag Care. 2001;7(4 Suppl):S103–12. [PubMed: 11392821]
  100. Leickly F E, Sears-Ewald D, Ownby D R. A comparative cost-effectiveness study of two treatment modalities for ragweed hay fever. Am J Rhinol. 1989;3(2):99–104.
  101. Leynadier F, Banoun L, Dollois B. et al. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy. 2001;31(7):988–96. [PubMed: 11467988]
  102. Liao E, Leahy M, Cummins G. The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis. Am J Manag Care. 2001;7(15 Suppl):S459–68. [PubMed: 11680261]
  103. Lichtenstein L M, Norman P S, Winkenwerder W L. A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies. Ann Intern Med. 1971;75(5):663–71. [PubMed: 4107763]
  104. Long A, McFadden C, DeVine D, et al. Management of allergic and nonallergic rhinitis. Evidence Report/Technology Assessment No. 54 (Prepared by New England Medical Center Evidence-based Practice Center under Contract No. 290-97-0019). AHRQ Publication No. 02-E024. Rockville, MD: Agency for Healthcare Research and Quality. May 2002.
  105. Lower T, Henry J, Mandik L. et al. Compliance with allergen immunotherapy. Ann Allergy. 1993;70(6):480–2. [PubMed: 8507043]
  106. Lundback B. Epidemiology of rhinitis and asthma. [Review]. Clin Exp Allergy 1998;(Suppl 2):3–10. [PubMed: 9678821]
  107. Mackowiak J I. The health and economic impact of rhinitis. Am J Manag Care. 1997;3:S8–S18.
  108. Malone D C, Lawson K A, Smith D H. et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol. 1997;99(1 Pt 1):22–7. [PubMed: 9003207]
  109. Manor O, Matthews S, Power C. Self-rated health and limiting longstanding illness: inter-relationships with morbidity in early adulthood. Int J Epidemiol. 2001;30(3):600–7. [PubMed: 11416091]
  110. McAllen M K. Hyposensitisation in grass pollen hay fever. A double blind trial of alumn precipitated pollen extract and depot emulsion pollen extract compared with placebo injections. Acta Allergol. 1969;24(6):421–31. [PubMed: 4910693]
  111. McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy. 1994;73(1):35–9. [PubMed: 8030800]
  112. Meltzer E O, Casale T B, Nathan R A. et al. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1999;83(4):311–7. [PubMed: 10541423]
  113. Meran A, Morse J, Gibbs T G. A cross-over comparison of acrivastine, pseudoephedrine and their combination in seasonal allergic rhinitis. Rhinology. 1990;28(1):33–40. [PubMed: 1970907]
  114. Moher D, Cook D J, Jadad A R. et al. Assessing the quality of randomised trials: current issues and future directions. Int J Tech Assess Health Care. 1996;12(2):195–208. [PubMed: 8707495]
  115. Moher D, Schulz K F, Altman D. et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. [Review] JAMA. 2001;285(15):1987–91. [PubMed: 11308435]
  116. Möller C, Dreborg S, Ferdousi H A. et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study) J Allergy Clin Immunol. 2002;109(2):251–6. [PubMed: 11842293]
  117. Moon J S, Choi S O. Environmental controls in reducing house dust mites and nasal symptoms in patients with allergic rhinitis. Yonsei Med J. 1999;40(3):238–43. [PubMed: 10412335]
  118. Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy. 1988;43(7):523–9. [PubMed: 3148282]
  119. Naclerio R, Solomon W. Rhinitis and inhalant allergens. [Review] JAMA. 1997;278(22):1842–8. [PubMed: 9396645]
  120. Naclerio R M, Proud D, Moylan B. et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol. 1997;100(3):293–300. [PubMed: 9314339]
  121. Nash DB, Sullivan SD, Mackowiak J. Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting. Am J Manag Care 2000;6(1 Suppl):S3–15; quiz S19–20. [PubMed: 11009751]
  122. National Heart Lung and Blood Institute. Practical guide for the diagnosis and management of asthma. NIH Publication No. 97-4053. Rockville, MD: National Institutes of Health, 1997.
  123. National Institute of Allergy and Infectious Diseases, National Institutes of Health. Allergy statistics. NIAID Fact Sheet. Bethesda, MD: National Institute of Allergy and Infectious Diseases. January 2002.
  124. National Institutes of Health. Fighting seasonal allergies. NIH Word on Health. Bethesda, MD: National Institutes of Health. June 2002.
  125. Negrini A C, Troise C, Voltolini S. et al. Oral antihistamine/decongestant treatment compared with intranasal corticosteroids in seasonal allergic rhinitis. Clin Exp Allergy. 1995;25(1):60–5. [PubMed: 7537170]
  126. Nimmagadda SR, Evans R 3rd. Allergy: etiology and epidemiology. [Review]. Pediatr Rev 1999;20(4):111–5; quiz 116. [PubMed: 10208083]
  127. Norman P S, Lichtenstein L M, Kagey-Sobotka A. et al. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J Allergy Clin Immunol. 1982;70(4):248–60. [PubMed: 6181113]
  128. Ortolani C, Pastorello E A, Incorvaia C. et al. A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever. Allergy. 1994;49(1):13–21. [PubMed: 8198235]
  129. Oxford Centre for Evidence-based Medicine. Levels of evidence. May 2001. Produced by Phillips B, Ball C, Sackett D, et al., since November 1998. Available at: http://163.1.96.10/docs/levels.html#levels. Accessed May 30, 2002.
  130. Panda N K, Mann S B. Comparative efficacy and safety of terfenadine with pseudoephedrine and terfenadine alone in allergic rhinitis. Otolaryngol Head Neck Surg. 1998;118(2):253–5. [PubMed: 9482562]
  131. Parikh A, Scadding G K. Seasonal allergic rhinitis. BMJ. 1997;314:1392–5. [PMC free article: PMC2126668] [PubMed: 9161315]
  132. Parker W A, Whisman B A, Apaliski S J. et al. The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis. J Allergy Clin Immunol. 1989;84(5 Pt 1):667–77. [PubMed: 2809024]
  133. Pastorello E A, Pravettoni V, Incorvaia C. et al. Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever. Allergy. 1992;47(4 Pt 1):281–90. [PubMed: 1443446]
  134. Pedersen P A, Weeke E R. Asthma and allergic rhinitis in the same patients. Allergy. 1983;38(1):25–9. [PubMed: 6837893]
  135. Pence H L, Mitchell D Q, Greely R L. et al. Immunotherapy for mountain cedar pollinosis. A double-blind controlled study. J Allergy Clin Immunol. 1976;58(1 Pt 1):39–50. [PubMed: 780406]
  136. Petersson G. Allergy practice and the otolaryngologist. Curr Opin Otolaryngol Head Neck Surg. 1995;3(3):218–23.
  137. Purello-D'Ambrosio F, Isola S, Ricciardi L. et al. A controlled study on the effectiveness of loratadine in combination with flunisolide in the treatment of nonallergic rhinitis with eosinophilia (NARES) Clin Exp Allergy. 1999;29(8):1143–7. [PubMed: 10457120]
  138. Radcliffe M J, Lampe F C, Brostoff J. Allergen-specific low-dose immunotherapy in perennial allergic rhinitis: a double-blind placebo-controlled crossover study. J Investig Allergol Clin Immunol. 1996;6(4):242–7. [PubMed: 8844501]
  139. Ragusa F V, Passalacqua G, Gambardella R. et al. Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience. J Investig Allergol Clin Immunol. 1997;7(3):151–4. [PubMed: 9252872]
  140. Rak S, Heinrich C, Jacobsen L. et al. A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol. 2001;108(6):921–8. [PubMed: 11742269]
  141. Ratner P H, van Bavel J H, Martin B G. et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract. 1998;47(2):118–25. [PubMed: 9722799]
  142. Ray N F, Baraniuk J N, Thamer M. et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol. 1999;103(3 Pt 1):401–7. [PubMed: 10069872]
  143. Reilly M C, Tanner A, Meltzer E O. Work, classroom and activity impairment instruments: validation studies in allergic rhinitis. Clin Drug Invest. 1996;11:278–88.
  144. Reisman R E, Mauriello P M, Davis G B. et al. A double-blind study of the effectiveness of a high-efficiency particulate air (HEPA) filter in the treatment of patients with perennial allergic rhinitis and asthma. J Allergy Clin Immunol. 1990;85(6):1050–7. [PubMed: 2191991]
  145. Revicki D A, Leidy N K, Brennan-Diemer F. et al. Development and preliminary validation of the multiattribute Rhinitis Symptom Utility Index. Qual Life Res. 1998;7(8):693–702. [PubMed: 10097618]
  146. Ross R N. The costs of allergic rhinitis. Am J Manag Care. 1996;2:285–90.
  147. Ross R N, Nelson H S, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies. Clin Ther. 2000;22(3):342–50. [PubMed: 10963288]
  148. Royal College of Physicians; Royal College of Pathologists. Good allergy practice--standards of care for providers and purchasers of allergy services within the National Health Service. Clin Exp Allergy. 1995;25(7):586–95. [PubMed: 8521176]
  149. Santilli J, Nathan R, Glassheim J. et al. Patients receiving immunotherapy report it is effective as assessed by the rhinitis outcomes questionnaire (ROQ) in a private practice setting. Ann Allergy Asthma Immunol. 2001;86(2):219–21. [PubMed: 11258693]
  150. Santos R, Cifaldi M, Gregory C. et al. Economic outcomes of a targeted intervention program: the costs of treating allergic rhinitis patients. Am J Manag Care. 1999;5(4 Suppl):S225–34. [PubMed: 10387543]
  151. Scadding G K, Richards D H, Price M J. Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis. Clin Otolaryngol Allied Sci. 2000;25(6):551–7. [PubMed: 11122298]
  152. Schädlich P K, Brecht J G. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics. 2000;17:37–52. [PubMed: 10747764]
  153. Settipane G A. Allergic rhinitis--update. Otolaryngol Head Neck Surg. 1986;94(4):470–5. [PubMed: 3086809]
  154. Settipane R J, Hagy G W, Settipane G A. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. [Review] Allergy Proc. 1994;15(1):21–5. [PubMed: 8005452]
  155. Shapiro G G, Wighton T G, Chinn T. et al. House dust mite avoidance for children with asthma in homes of low-income families. J Allergy Clin Immunol. 1999;103(6):1069–74. [PubMed: 10359888]
  156. Sheikh A, Hurwitz B. House dust mite avoidance measures for perennial allergic rhinitis (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software.
  157. Simpson R J. Budesonide and terfenadine, separately and in combination, in the treatment of hay fever. Ann Allergy. 1994;73(6):497–502. [PubMed: 7998664]
  158. Skoner D P. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. [Review] J Allergy Clin Immunol. 2001;108(1 Suppl):S2–8. [PubMed: 11449200]
  159. Spector S L. Overview of comorbid associations of allergic rhinitis. [Review] J Allergy Clin Immunol. 1997;99(2):S773–80. [PubMed: 9042070]
  160. Stahl E, van Rompay W, Wang E C. et al. Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2000;84(4):397–402. [PubMed: 10795647]
  161. Storms W, Meltzer E O, Nathan R A. et al. The economic impact of allergic rhinitis. J Allergy Clin Immunol. 1997;99:S820–4.
  162. Strachan D, Sibbald B, Weiland S. et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC) Ped Allergy Immunol. 1997;8(4):161–76. [PubMed: 9553981]
  163. Stroup D F, Berlin J A, Morton S C. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. [Review] JAMA. 2000;283(15):2008–12. [PubMed: 10789670]
  164. Sullivan S D, Weiss K B. Health economics of asthma and rhinitis. II. Assessing the value of interventions. J Allergy Clin Immunol. 2001;107(2):203–10. [PubMed: 11174182]
  165. Sussman G L, Mason J, Compton D. et al. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104(1):100–6. [PubMed: 10400846]
  166. Tanner L A, Reilly M, Meltzer E O. et al. Effect of fexofenadine HCl on quality of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis. Am J Manag Care. 1999;5(4 Suppl):S235–47.
  167. The SAS Institute. The SAS System for Windows [computer program]. Release 8.02. Cary, NC: The SAS Institute, Inc.; 2001.
  168. Thompson A K, Juniper E, Meltzer E O. Quality of life in patients with allergic rhinitis. [Review] Ann Allergy Asthma Immunol. 2000;85(5):338–48. [PubMed: 11101172]
  169. Trotter J P. The treatment of seasonal allergic rhinitis: cost implications of pharmacotherapy for managed care. Manag Care Interface. 2000;13(1):60–2. [PubMed: 10747693]
  170. Trotto N E. Asthma, rhinitis, sinusitis, urticaria. Patient Care. 1999;33(1):115–39.
  171. Turkeltaub P C, Gergen P J. Prevalence of upper and lower respiratory conditions in the US population by social and environmental factors: data from the second National Health and Nutrition Examination Survey, 1976 to 1980 (NHANES II) Ann Allergy. 1991;67(2 Pt 1):147–54. [PubMed: 1867453]
  172. Van Metre T E, Adkinson N F, Amodio F J. et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol. 1982;69(2):181–93. [PubMed: 7056949]
  173. Van Metre T E, Adkinson N F Jr, Amodio F J. et al. A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol. 1980;66(6):500–13. [PubMed: 6159384]
  174. Varney V A, Gaga M, Frew A J. et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ. 1991;302(6771):265–9. [PMC free article: PMC1668945] [PubMed: 1998791]
  175. Vuurman E F P M, van Veggel L M A, Sanders R L. et al. Effects of Semprex-D and diphenhydramine on learning in young adults with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1996;76(3):247–52. [PubMed: 8634878]
  176. Walker S M, Pajno G B, Lima M T. et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol. 2001;107(1):87–93. [PubMed: 11149996]
  177. Weiler J M, Bloomfield J R, Woodworth G G. et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med. 2000;132(5):354–63. [PubMed: 10691585]
  178. Weiss K B, Sullivan S D. The health economics of asthma and rhinitis. I. Assessing the economic impact. [Review] J Allergy Clin Immunol. 2001;107(1):3–8. [PubMed: 11149982]
  179. Weyer A, Donat N, L'Heritier C. et al. Grass pollen hyposensitization versus placebo therapy. I. Clinical effectiveness and methodological aspects of a pre-seasonal course of desensitization with a four-grass pollen extract. Allergy. 1981;36(5):309–17. [PubMed: 7032341]
  180. White P, Smith H, Baker N. et al. Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy? Clin Exp Allergy. 1998;28(3):266–70. [PubMed: 9543074]
  181. Williams B O, Hull H, McSorley P. et al. Efficacy of acrivastine plus pseudoephedrine for symptomatic relief of seasonal allergic rhinitis due to mountain cedar. Ann Allergy Asthma Immunol. 1996;76(5):432–8. [PubMed: 8630717]
  182. Wilson A, Dempsey O J, Sims E J. et al. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clin Exp Allergy. 2000;30(6):833–8. [PubMed: 10848901]
  183. Wood R A, Johnson E F, Van Natta M L. et al. A placebo-controlled trial of a HEPA air cleaner in the treatment of cat allergy. Am J Respir Crit Care Med. 1998;158(1):115–20. [PubMed: 9655716]
  184. Yawn B P, Yunginger J W, Wollan P C. et al. Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. J Allergy Clin Immunol. 1999;103(1 Pt 1):54–9. [PubMed: 9893185]
  185. Zeiger R S, Schatz M. Effect of allergist intervention on patient-centered and societal outcomes: allergists as leaders, innovators, and educators. [Review] J Allergy Clin Immunol. 2000;106(6):995–1018. [PubMed: 11112881]
  186. Zenner H P, Baumgarten C, Rasp G. et al. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. J Allergy Clin Immunol. 1997;100(1):23–9. [PubMed: 9257783]

Views

  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...